ESH Video

4th How to Diagnose and Treat Acute Leukaemias

4th How to Diagnose and Treat Acute Leukaemias
March 01 - March 03, 2024 - Stockholm, Sweden - #ESHAL2024
Chairs : Hervé Dombret, Gert Ossenkoppele, Christoph Röllig, Wendy Stock


4th How to Diagnose and Treat:
Acute Leukaemias

March 1-3, 2024 – Stockholm, Sweden

Chairs: Hervé Dombret, Gert Ossenkoppele, Christoph Röllig, Wendy Stock



About the Conference:

ESH How to Diagnose and Treat meetings are disease-specific meetings that address up to date diagnostic and clinical management which is greatly facilitated by and discussion of real clinical cases. Intensive interaction between the speakers and participants will be helpful in spreading knowledge.
Novel and still evolving insights into the biology and diagnosis of acute myeloid leukaemias (AMLs) and acute lymphoblastic leukaemias (ALL), has resulted in new drug approvals and new therapeutic options to treat newly-diagnosed as well as relapsed/refractory disease. Recently updates on prognostication and classification of acute leukemias have been published which will be discussed in various sessions
The programme of this “How to Diagnose and Treat: Acute Leukaemias” includes genomic analysis and cutting-edge technics in routine diagnosis, targeted therapies and standard of care treatments allogeneic haematopoietic stem cell (HSCT) transplantation and innovative immunotherapies, as well as diagnosis and management of rare acute leukaemia subtypes. Clonal hematopoiesis will be covered in detail. Novel trial designs instrumental for smarter drug development is discussed in a separate session.


This educational conference has been approved for 18 CME-CPD credit points by the European Board for Accreditation in Haematology (EBAH).


Conference Main Scientific Topics:

– Diagnosis and treatment of rare diseases
– Novel treatments
– Dilemmas in AML
– Debate: MRD conversion before alloSCT
– Innovative trial designs to accelerate advances in leukaemia
– Immunotherapy in AML and ALL
– VenAza or intensive chemo as 1L treatment before allo HCT
– Debate: Transplant is no longer first line approach to Ph+ ALL
– Leukaemia treatment challenges
– Clonal haematopoiesis and germline predisposition


Learning Objectives:

– Knowledge of Classification of ALL and AML
– Insight in prognosis of ALL and AML
– Application of MRD
– Knowledge of established and novel treatment options in ALL and AML
– Indications of alloSCT
– Management of challenging subgroups of AML and ALL
– Controversies on clinical trials and treatment options

The programme will include:

– Plenary Sessions
– Interactive Case Presentations
– Roundtables
– Panel Discussions
– Debates
– Poster Walks
– Meet the Expert Sessions
– Voting technology



CLICK HERE to access the programme.


Abstract submission

Submission for abstracts and clinical cases are closed!

Clinical Cases and abstracts are eligible to be selected for an oral or a poster presentation.


Clinical Case Presentation:

  • Clinical cases must be relevant to the topic of the meeting. 
  • Maximum number of words: 500 
  • Your clinical case will be submitted to peer review. 


  • Your abstract can be structured (eg Objectives, Methods, Results, Conclusions) or unstructured. 
  • Maximum number of words: 500 
  • Your abstract will be submitted to peer review.


We accept “encore” abstract.

Presentation of data at this conference will not jeopardize acceptance of the same at the following ASH congress.


Friday, March 1st, 2024

Interactive case studies for an IDH1 mutated patient ineligible for intensive chemotherapy – From diagnosis to treatment
Chair: Courtney DiNardo (Houston)
Speakers: Courtney DiNardo (Houston), Lars Fransecky (Kiel), Adriano Venditti (Rome)

This symposium is organised and sponsored by Servier


You can use the code “Meet Stockholm” on the Strawberry Hotels website to make a reservation for your accommodation at the Hotel of the Conference (Hotel Clarion).



Hotel Clarion
Ringvägen 98
10460 Stockholm, Sweden


Corporate partners

With the support of*:


Major Conference Partner

Level 1 Conference Partners


Level 2 Conference Partners

Supporting Conference Partners


*ESH conference programmes are developed in strict scientific independence
with no input from corporate sponsors.



Educational Grants



The registration fee for the ESH 4th How to Diagnose and Treat Acute Leukaemias is:

– 600€ for fully trained

– 300€ for in-training *

– 300€ Allied Health Professionals

– 600€ for Corporate

*A proof will be requested to confirm your status.


ESH is pleased to offer BSH, DGHO and PTHiT Members a 20% discount on the conference registration fees.


This fee includes:

Your seat in the Conference Room

The conference materials,

Welcome cocktail, luncheons, refreshments throughout the conference.

Your seat in the conference will be definitively reserved upon receipt of your fee.


Cancellation policy of registration fee :

In case of cancellation, up until two months prior to the beginning of the meeting, your registration fee will be reimbursed in full (less bank charges). If the cancellation is notified between 60 to 15 days prior to the beginning of the meeting, 50% of the registration fee will be reimbursed (less bank charges). Cancellations notified 15 days before the meeting will not be reimbursed. For credit card payments please register on-line first. Please note that ESH can accept VISA and MASTERCARD/EUROCARD.